The U.S. Food and Drug Administration (FDA) announced on May 14, 2025, the approval of the expanded use of Merck's cancer drug Welireg. This approval is for the treatment of two types of adrenal gland tumors.
Specifically, Welireg is now approved for patients aged 12 years and older with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma. This makes Welireg the only available therapy in the U.S. for eligible patients with these rare tumors.
This regulatory milestone significantly broadens Welireg's market potential and reinforces its role in Merck's oncology portfolio. The approval addresses a critical unmet medical need for patients with these challenging conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.